LYTIX — Lytix Biopharma AS Cashflow Statement
0.000.00%
- NOK452.17m
- NOK402.11m
- NOK3.99m
Annual cashflow statement for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | NAS | NAS | NAS | NAS | NAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -32.4 | -42.1 | -48.1 | -56.1 | -87.9 |
Depreciation | |||||
Non-Cash Items | 5.76 | 8.4 | 4.05 | 1.38 | 4.18 |
Other Non-Cash Items | |||||
Changes in Working Capital | -10.2 | 9.34 | -1.04 | 1.15 | -13.2 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -36.8 | -24.3 | -44.6 | -52.6 | -96 |
Capital Expenditures | — | — | 0 | -0.154 | -0.049 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | — | 0.138 | -49.2 | 29.8 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | — | 0.138 | -49.4 | 29.7 |
Financing Cash Flow Items | — | — | -11.5 | -0.055 | -0.003 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.005 | 40 | 213 | -0.749 | -0.943 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -36.8 | 15.7 | 169 | -103 | -67.2 |